Almotriptan (BioDeep_00000600176)
代谢物信息卡片
Almotriptan
化学式: C17H25N3O2S (335.1667)
中文名称: 盐酸阿莫曲坦-d6
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CN(C)CCC1=CNC2=C1C=C(C=C2)CS(=O)(=O)N3CCCC3
InChI: InChI=1S/C17H25N3O2S/c1-19(2)10-7-15-12-18-17-6-5-14(11-16(15)17)13-23(21,22)20-8-3-4-9-20/h5-6,11-12,18H,3-4,7-10,13H2,1-2H3
描述信息
N - Nervous system > N02 - Analgesics > N02C - Antimigraine preparations > N02CC - Selective serotonin (5ht1) agonists
D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D017366 - Serotonin Receptor Agonists
C78272 - Agent Affecting Nervous System > C47794 - Serotonin Agonist
Almotriptan is a selective agonist of 5-HT 1B/1D Receptor. Almotriptan can used in study of migraine attacks[1].
同义名列表
1 个代谢物同义名
数据库引用编号
9 个数据库交叉引用编号
- ChEBI: CHEBI:520985
- KEGGdrug: D86136
- KEGGdrug: D02824
- PubChem: 123606
- Metlin: METLIN43879
- DrugBank: DB00918
- ChEMBL: CHEMBL1505
- CAS: 154323-57-6
- medchemexpress: HY-B0383A
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
| 亚细胞结构定位 | 关联基因列表 |
|---|
文献列表
- Nancy Abdel Hamid Abou Youssef, Abeer Ahmed Kassem, Ragwa Mohamed Farid, Fatma Ahmed Ismail, Magda Abd Elsamea El-Massik, Nabila Ahmed Boraie. A novel nasal almotriptan loaded solid lipid nanoparticles in mucoadhesive in situ gel formulation for brain targeting: Preparation, characterization and in vivo evaluation.
International journal of pharmaceutics.
2018 Sep; 548(1):609-624. doi:
10.1016/j.ijpharm.2018.07.014. [PMID: 30033394] - E Castagno, M Lupica, S Viola, F Savino, R Miniero. Creatin-kinase elevation after accidental ingestion of almotriptan in an 18-month-old girl.
Minerva pediatrica.
2014 Feb; 66(1):95-7. doi:
NULL. [PMID: 24608586] - Iain P Fraser, Lingling Han, Tae H Han, Chi-Chung Li, David Hreniuk, S Aubrey Stoch, John A Wagner, Steven Linder, Paul Winner. Pharmacokinetics and tolerability of rizatriptan in pediatric migraineurs in a randomized study.
Headache.
2012 Apr; 52(4):625-35. doi:
10.1111/j.1526-4610.2011.02069.x. [PMID: 22289113] - R Nageswara Rao, K Guruprasad, Ch Gangu Naidu, B Raju, R Srinivas. LC-ESI-MS/MS determination of in vivo metabolites of almotriptan in rat plasma, urine and feces: application to pharmacokinetics.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2012 Apr; 891-892(?):44-51. doi:
10.1016/j.jchromb.2012.02.017. [PMID: 22406349] - Konda Ravikumar, Babu Rao Chandu, Balasekhara Reddy Challa, Kottapalli B Chandrasekhar. Method development and validation of almotriptan in human plasma by HPLC tandem mass spectrometry: application to pharmacokinetic study.
Scientia pharmaceutica.
2012 Apr; 80(2):367-78. doi:
10.3797/scipharm.1112-01. [PMID: 22896823] - M A Calatayud-Pascual, C Balaguer-Fernández, C E Serna-Jiménez, S Del Rio-Sancho, A Femenía-Font, V Merino, A López-Castellano. Effect of iontophoresis on in vitro transdermal absorption of almotriptan.
International journal of pharmaceutics.
2011 Sep; 416(1):189-94. doi:
10.1016/j.ijpharm.2011.06.039. [PMID: 21736929] - Manthena V S Varma, Bo Feng, R Scott Obach, Matthew D Troutman, Jonathan Chupka, Howard R Miller, Ayman El-Kattan. Physicochemical determinants of human renal clearance.
Journal of medicinal chemistry.
2009 Aug; 52(15):4844-52. doi:
10.1021/jm900403j. [PMID: 19445515] - R Scott Obach, Franco Lombardo, Nigel J Waters. Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals.
2008 Jul; 36(7):1385-405. doi:
10.1124/dmd.108.020479. [PMID: 18426954] - X Cabarrocas, M Salva, M Pavesi, J Costa. Ethanol does not significantly affect the bioavailability of almotriptan: an open, randomized, crossover, single-dose, phase I clinical trial in healthy volunteers.
International journal of clinical pharmacology and therapeutics.
2006 Sep; 44(9):443-8. doi:
10.5414/cpp44443. [PMID: 16995333] - J Aubets, A Cardenas, M Salva, J M Jansat, A Martinez-Tobed, J M Palacios. Disposition and metabolism of almotriptan in rats, dogs and monkeys.
Xenobiotica; the fate of foreign compounds in biological systems.
2006 Sep; 36(9):807-23. doi:
10.1080/00498250600802508. [PMID: 16971345] - Miguel J A Láinez. Rizatriptan in the treatment of migraine.
Neuropsychiatric disease and treatment.
2006 Sep; 2(3):247-59. doi:
10.2147/nedt.2006.2.3.247. [PMID: 19412472] - J M Jansat, A Martinez-Tobed, E Garcia, X Cabarrocas, J Costa. Effect of food intake on the bioavailability of almotriptan, an antimigraine compound, in healthy volunteers: an open, randomized, crossover, single-dose clinical trial.
International journal of clinical pharmacology and therapeutics.
2006 Apr; 44(4):185-90. doi:
10.5414/cpp44185. [PMID: 16625988] - Janet D McEnroe, Joseph C Fleishaker. Clinical pharmacokinetics of almotriptan, a serotonin 5-HT(1B/1D) receptor agonist for the treatment of migraine.
Clinical pharmacokinetics.
2005; 44(3):237-46. doi:
10.2165/00003088-200544030-00002. [PMID: 15762767] - J McEwen, M Salva, J M Jansat, X Cabarrocas. Pharmacokinetics and safety of oral almotriptan in healthy male volunteers.
Biopharmaceutics & drug disposition.
2004 Oct; 25(7):303-11. doi:
10.1002/bdd.412. [PMID: 15386481] - Andrew J Dowson. Oral almotriptan: practical uses in the acute treatment of migraine.
Expert review of neurotherapeutics.
2004 May; 4(3):339-48. doi:
10.1586/14737175.4.3.339. [PMID: 15853532] - J R Baldwin, J C Fleishaker, N E Azie, B J Carel. A comparison of the pharmacokinetics and tolerability of the anti-migraine compound almotriptan in healthy adolescents and adults.
Cephalalgia : an international journal of headache.
2004 Apr; 24(4):288-92. doi:
10.1111/j.1468-2982.2004.00673.x. [PMID: 15030538] - Joseph C Fleishaker, Beth D Herman, Barbara J Carel, Nkechi E Azie. Interaction between ketoconazole and almotriptan in healthy volunteers.
Journal of clinical pharmacology.
2003 Apr; 43(4):423-7. doi:
10.1177/0091270003252242. [PMID: 12723463] - Josep M Jansat, Joan Costa, Pau Salvà, Francisco J Fernandez, Antonio Martinez-Tobed. Absolute bioavailability, pharmacokinetics, and urinary excretion of the novel antimigraine agent almotriptan in healthy male volunteers.
Journal of clinical pharmacology.
2002 Dec; 42(12):1303-10. doi:
10.1177/0091270002042012006. [PMID: 12463724] - ". New medications show promise for migraine sufferers.
Dentistry today.
2002 Oct; 21(10):70. doi:
". [PMID: 12382492] - Joseph C Fleishaker, Janet D McEnroe, Nkechi E Azie, Steven F Francom, Barbara J Carel. Cardiovascular effect of almotriptan in treated hypertensive patients.
Clinical pharmacology and therapeutics.
2002 Mar; 71(3):169-75. doi:
10.1067/mcp.2002.121372. [PMID: 11907491] - Jordi Gras, Jesús Llenas, Josep M Jansat, José Jáuregui, Xavier Cabarrocas, José M Palacios. Almotriptan, a new anti-migraine agent: a review.
CNS drug reviews.
2002; 8(3):217-34. doi:
10.1111/j.1527-3458.2002.tb00226.x. [PMID: 12353056] - J Gras, J Llupià, J Llenas, J M Palacios. Safety profile of almotriptan, a new antimigraine agent. Effects on central nervous system, renal function and respiratory dynamics.
Arzneimittel-Forschung.
2001 Sep; 51(9):726-32. doi:
10.1055/s-0031-1300106. [PMID: 11642004] - J C Fleishaker, K K Ryan, J M Jansat, B J Carel, D J Bell, M T Burke, N E Azie. Effect of MAO-A inhibition on the pharmacokinetics of almotriptan, an antimigraine agent in humans.
British journal of clinical pharmacology.
2001 May; 51(5):437-41. doi:
10.1046/j.1365-2125.2001.01367.x. [PMID: 11422001] - J C Fleishaker, K K Ryan, B J Carel, N E Azie. Evaluation of the potential pharmacokinetic interaction between almotriptan and fluoxetine in healthy volunteers.
Journal of clinical pharmacology.
2001 Feb; 41(2):217-23. doi:
10.1177/00912700122009917. [PMID: 11210405] - J C Fleishaker, T A Sisson, B J Carel, N E Azie. Lack of pharmacokinetic interaction between the antimigraine compound, almotriptan, and propranolol in healthy volunteers.
Cephalalgia : an international journal of headache.
2001 Feb; 21(1):61-5. doi:
10.1046/j.1468-2982.2001.00151.x. [PMID: 11298665] - J Gras, J Bou, J Llenas, A G Fernández, J M Palacios. Functional profile of almotriptan in animal models predictive of antimigraine activity.
European journal of pharmacology.
2000 Dec; 410(1):43-51. doi:
10.1016/s0014-2999(00)00877-3. [PMID: 11134655] - D Deleu, Y Hanssens. Current and emerging second-generation triptans in acute migraine therapy: a comparative review.
Journal of clinical pharmacology.
2000 Jul; 40(7):687-700. doi:
10.1177/00912700022009431. [PMID: 10883409] - J C Fleishaker, T A Sisson, B J Carel, N E Azie. Pharmacokinetic interaction between verapamil and almotriptan in healthy volunteers.
Clinical pharmacology and therapeutics.
2000 May; 67(5):498-503. doi:
10.1067/mcp.2000.106292. [PMID: 10824628]
